Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02620527 · ClinicalTrials.gov registry record
Concordance Between ctDNA Assay and FoundationOne
A clinical trial of Cancer and Neoplasms, sponsored by Foundation Medicine.
- Completed
- Registry status
- 1,400
- Enrollment target
- 1
- Study location
NCT02620527: Completed study of Cancer and Neoplasms, sponsored by Foundation Medicine.
NCT02620527 is a study of Cancer and Neoplasms that has completed, run by Foundation Medicine. The registered enrollment target is 1,400 participants, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02620527, a study of Cancer and Neoplasms, has completed, sponsored by Foundation Medicine.
- COMPLETED
- Registry status
- 1,400 participants
- Enrollment target
- 1
- Study location
Study Summary
Foundation Medicine Inc. (FMI) is interested in studying the concordance of genomic alterations between primary and/or metastatic surgical biopsies, and circulating tumor DNA (ctDNA) within different solid tumor types and has been developing an assay in order to do so.
Conditions Studied
Study Locations (1)
Massachusetts
- Foundation Medicine - Cambridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,400 participants |
| Start Date | 2014-11 |
| Est. Completion | 2017-12 |
What the finished NCT02620527 record still lists
NCT02620527 is an observational study that tracks outcomes without assigning an intervention. Its 1,400 participants enrollment target places it among the larger protocols in the corpus, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (60% lower).
The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT02620527 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02620527 about?
NCT02620527 is a clinical study titled "Concordance Between ctDNA Assay and FoundationOne". Foundation Medicine Inc. (FMI) is interested in studying the concordance of genomic alterations between primary and/or metastatic surgical biopsies, and circulating tumor DNA (ctDNA) within different solid tumor types and has been developing an assay in order to do so.
What is the current status of trial NCT02620527?
This trial is currently completed. The enrollment target is 1,400 participants. The study started on 2014-11. Estimated completion is 2017-12.
What conditions does trial NCT02620527 study?
This clinical trial studies the following conditions: Cancer, Neoplasms, Circulating Tumor DNA, Genomic Testing, Genomic Alterations.
Who is sponsoring clinical trial NCT02620527?
This trial is sponsored by Foundation Medicine, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02620527 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02620527's enrollment target sits among peer trials
1,400 72nd of 615 higher than 544 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02205762 · 1,400 participants · Phase 2
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
- NCT02445222 · 1,400 participants · Phase 3
CAR-T Long Term Follow Up (LTFU) Study
- NCT03145077 · 1,400 participants · NA
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body
- NCT04250857 · 1,400 participants
HeartStart FRx Defibrillator Event Registry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia